Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Santhera
Biotech
Santhera offloads North American rights for DMD med to Catalyst
Santhera is bidding farewell to critical commercialization rights for vamorolone, selling North American access to Catalyst for up to $231 million.
Max Bayer
Jun 20, 2023 9:53am
Santhera loses interest in pulmonary drug to focus on DMD
Oct 31, 2022 10:25am
Santhera sidelined by manufacturing delay for DMD drug
Jun 29, 2022 10:55am
Novartis alums unveil their next act—Chutes & Ladders
Nov 6, 2020 9:30am
Santhera outlines cuts, and they are deep, as CMO hits the exit
Nov 2, 2020 7:35am
Santhera flunks DMD phase 3, prompting restructuring
Oct 6, 2020 8:05am